Scientific Advisory Board
AnaptysBio’s scientific advisory board is involved in advancing the company’s SHM-XEL™ technology platform and its broad applications in antibody generation and protein engineering.
Michael Neuberger, Ph.D.
Medical Research
Council, Cambridge, England
Dr. Neuberger is currently Joint Head of Division of Protein and Nucleic Acid
Chemistry and member of Executive Committee, of the Medical Research Council,
in Cambridge, England. Dr. Neuberger’s major research interests are directed
towards understanding the biochemical processes and the physiological pathways
by which antibody diversity is created. Dr. Neuberger was elected as a Fellow
of the Royal Society in 1993, and is a Trustee of the Isaac Newton Trust. He
has been awarded numerous awards in recognition of his scientific contributions
in the antibody field, including the Novartis Medal (Biochemical Society), the
William Bate Hardy Prize, the GlaxoSmithKline Medal (Royal Society) and the
Dannie-Heineman Prize (Akademie der Wissenschaften zu Disease).
He is also a past or present member of a number of academic and editorial
boards and has consulted for various companies interested in antibody
engineering including Cambridge Antibody Technology (CAT), Xenova-Cantab, and
Therapeutic Human Polyclonals. He is the lead inventor on various granted
patents and applications in the field of antibody engineering.
Dr. Neuberger received his Bachelors degree at Cambridge University and his
doctorate work at the University of London in the laboratory of B.S. Hartley.
Matthew Scharff, M.D.
Albert Einstein
College of Medicine
Dr. Scharff first worked as a Research Associate at the NIH before he joined
the Departments of Cell Biology and Medicine at the Albert Einstein College of
Medicine, where he has served as the Chairman of the Department of Cell
Biology, Director of the Division of Biological Sciences and Director of the
Cancer Center.
Dr. Scharff has devoted most of his research career to studying the production
of antibodies by B cells, the role of antibodies in resistance to infection and
in causing autoimmunity and the mechanisms responsible for the generation of
antibody diversity. He is currently the Harry Eagle Professor of Cancer
Research and a Distinguished Professor at the Albert Einstein College of
Medicine. He is a member of the National Academy of Sciences, the American
Academy of Arts and Sciences and has received numerous awards including the
American Association of Immunologists Award for Excellence in Mentoring in 1998
and the Mayor of New York's Lifetime Achievement Award for Excellence in
Science and Technology, 2003.
Dr. Scharff received his undergraduate education from Brown University and was
awarded an honorary Doctor of Medical Sciences degree from that University in
1994. He received his MD from New York University School of Medicine and was a
house officer in medicine for the Harvard Service at the Boston City Hospital.
Phillip
Patten, Ph.D.,
Pioneer
Hi-Bred International, Inc.
Dr. Patten currently holds the position of senior research fellow at Pioneer Hi-Bred International, Inc. Previously, Dr. Patten served as senior vice president of biology at Achaogen, Inc., and as vice president of science and technology at Maxygen, where he was a founding scientist and developed the company's gene shuffling technology. He earned his bachelor's degree in biology at the California Institute of Technology and his Ph.D. at Stanford University. He was awarded a Damon Runyon Postdoctoral Fellowship at U.C. Berkeley where he did pioneering work on the structural basis of antibody affinity maturation.
Therapeutic Advisory Board
AnaptysBio’s therapeutic advisory board is primarily involved in advancing the company's product pipeline, including the identification of potential antibody targets, establishing profiles for product programs and planning development strategies.
David L. Lacey, M.D
Industry
Consultant
Dr. Lacey is a former senior vice president and head of discovery research at Amgen with over 30 years of basic and clinical research experience. Dr. Lacey played a fundamental role in the discovery of the OPG/RANKL/RANK pathway at Amgen as well as the development of the anti-RANKL human antibody known as denosumab. He was most recently responsible for leading a group of over 1,200 FTEs in Amgen's discovery research unit across hundreds of preclinical projects in hematology/oncology, inflammation, metabolic disorders and neuroscience. Dr. Lacey received an M.D. from the University of Colorado and was trained in pathology at the Washington University Medical Center, St. Louis, MO.
Michael Gallatin, Ph.D.
Senior
Advisor, Frazier Healthcare
Dr. Gallatin is a former vice president and scientific director of ICOS Corporation, where his responsibilities included discovery, preclinical research, medicinal chemistry and process chemistry groups, including those responsible for worldwide development and launch of tadalafil (Cialis®). Subsequently, Dr. Gallatin helped found Stromedix, which focused on novel treatments for chronic fibrotic diseases and was recently acquired by Biogen Idec. Dr. Gallatin also co-founded and was president of Calistoga Pharmaceuticals, the first company to demonstrate clinical benefit of isoform-selective PI3 kinase inhibition, subsequently acquired by Gilead. He has also been a member of the Scientific Advisory Boards of the Keystone Symposia, Caprion, and the University of Texas Department of Chemistry, a member of the BioSeek Board of Directors and has recently also joined the Board of Directors of the Benaroya Research Institute. Dr. Gallatin received his Ph.D. from the University of Alberta’s Department of Immunology, and discovered the first cell adhesion molecule implicated in site-selective leukocyte traffic while a Damon Runyon-Walter Winchell and American Cancer Society fellow at Stanford University in the laboratory of Dr. Irving Weissman. Dr. Gallatin is a former faculty member of the Fred Hutchinson Cancer Center and is currently a senior advisor to Frazier Healthcare.
Jan
de Vries, Ph.D.
Industry
Consultant
Dr. de Vries is the former head of the Novartis Research Institutes for BioMedical Research in Basel, Switzerland. Prior to that, he was head of the Novartis Research Institute in Vienna and global head of the Disease Area Autoimmunity, Transplantation and Inflammation. While at Novartis, Dr. de Vries led the early development of many drugs that are now on the market or in late-stage clinical development, including Elidel® for the treatment of atopic dermatitis, Ilaris® (canakinumab) for the treatment of various chronic inflammatory diseases and diabetes, Gilenia® for the treatment of multiple sclerosis and AIN-457, an IL-17 mab for the treatment of autoimmune diseases. Dr. de Vries joined Novartis from the DNAX Research Institute for Molecular Biological Research in Palo Alto, California, where he was director of the Immunology department from 1989-1997. From 1985-1989, he was director of the Schering-Plough Institute for Immunological Research in Lyon, France. He has held various academic positions at the Netherlands Cancer Institute in Amsterdam, where he was head of the Department of Immunology from 1979-1985. Dr. de Vries received his Ph.D. in Immunology from the University of Amsterdam and spent two years as a visiting scientist at the University of California, San Diego.
Nick Lydon, Ph.D.
Granite Biopharma, LLC
Dr. Lydon has extensive experience in drug discovery and development and is a recipient of the Lasker Prize and other awards for his achievements in medicine. Before founding his current consulting company, Granite Biopharma, LLC, Dr. Lydon served as vice president, small molecule drug discovery, at Amgen. Prior to joining Amgen, he was founder, CEO and president of Kinetix Pharmaceuticals, Inc., a biotechnology company focused on the discovery and development of selective protein kinase inhibitors, a number of which are now advancing through clinical development. Kinetix was acquired by Amgen in 2000.
Prior to Kinetix, Dr. Lydon worked at CIBA-GEIGY, in Basel, Switzerland, where he was responsible for the protein kinase inhibitor program. He and his team identified a number of protein kinase inhibitors. The most advanced drug from this program is Gleevec®, a selective Bcr-Abl inhibitor for the treatment of chronic myelogenous leukemia (CML). Dr. Lydon began his pharmaceutical career at Schering-Plough Corporation, where his research involved studies on recombinant alpha, beta, and gamma interferons.
In 2009, Dr. Lydon was awarded the Lasker Prize for his work on developing
Gleevec®, converting a fatal cancer into a manageable chronic condition. Other
awards include the Warren Alpert Foundation Prize, the AACR-Bruce F. Cain
Memorial Award and the Charles F. Kettering Prize from the General Motors
Cancer Research Foundation for his contributions to the discovery and
development of Gleevec®.
Dr. Lydon earned a B.S. in biochemistry from the University of Leeds, England,
and received his Ph.D. in biochemistry from the Medical Sciences Institute,
University of Dundee, Scotland. His thesis involved research work on adenylate
cyclase and cAMP dependent protein kinase. Dr. Lydon currently serves as
an advisor for Avalon Ventures.